Uniqure NV (NASDAQ:QURE) – Investment analysts at SunTrust Banks lowered their Q3 2019 earnings per share (EPS) estimates for Uniqure in a research report issued to clients and investors on Monday, July 29th, Zacks Investment Research reports. SunTrust Banks analyst J. Lee now anticipates that the biotechnology company will earn ($0.82) per share for the quarter, down from their prior estimate of ($0.73). SunTrust Banks has a “Buy” rating and a $76.00 price objective on the stock. SunTrust Banks also issued estimates for Uniqure’s Q4 2019 earnings at ($0.72) EPS, FY2019 earnings at ($3.10) EPS and FY2020 earnings at ($2.70) EPS.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The company had revenue of $2.47 million during the quarter, compared to analyst estimates of $1.53 million.
Several other equities research analysts also recently commented on QURE. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research report on Friday, August 2nd. BidaskClub downgraded shares of Uniqure from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 8th. Guggenheim downgraded shares of Uniqure from a “buy” rating to a “neutral” rating in a research report on Monday, July 29th. HC Wainwright set a $73.00 target price on shares of Uniqure and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $94.00 target price (up from $81.00) on shares of Uniqure in a research report on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $78.18.
Shares of QURE traded down $3.08 during mid-day trading on Thursday, reaching $53.13. The company had a trading volume of 569,082 shares, compared to its average volume of 585,542. The company’s 50 day simple moving average is $63.57 and its 200 day simple moving average is $60.77. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.07 and a current ratio of 8.07. Uniqure has a 1-year low of $21.98 and a 1-year high of $82.49. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of -22.71 and a beta of 0.94.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $56.48, for a total transaction of $451,840.00. Following the completion of the transaction, the chief executive officer now owns 391,230 shares in the company, valued at approximately $22,096,670.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Philip Astley-Sparke sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $63.63, for a total transaction of $381,780.00. Following the transaction, the director now owns 18,872 shares of the company’s stock, valued at approximately $1,200,825.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,460 shares of company stock valued at $2,413,195. Company insiders own 2.91% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Harvest Group Wealth Management LLC bought a new stake in shares of Uniqure in the 1st quarter valued at $26,000. Legal & General Group Plc increased its stake in shares of Uniqure by 264.2% in the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 700 shares in the last quarter. Pearl River Capital LLC bought a new stake in shares of Uniqure in the 1st quarter valued at $32,000. Griffin Asset Management Inc. bought a new stake in shares of Uniqure in the 2nd quarter valued at $39,000. Finally, US Bancorp DE increased its stake in shares of Uniqure by 275.5% in the 2nd quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 427 shares in the last quarter. Institutional investors own 59.88% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington’s disease; and AMT-126, for the treatment of heart failure.